The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Platelet count response
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Proportion of subjects with refractory iTTP
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Proportion of subjects with recurrent disease
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Time to normalization of organ damage marker levels
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Total duration of hospitalization stays
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Duration of intensive care unit (ICU) stay
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Duration of therapeutic PE
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Proportion of patients achieving clinical response
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Time to ADAMTS13 activity ≥ 20%
Timeframe: From index date up to 12 weeks after last dose of caplacizumab
Number of participants with Adverse event
Timeframe: From index date up to 12 weeks after last dose of caplacizumab